Table 3.
Adjusted difference of hemostatic measurements between users of CEE and E2, stratified by the use of progestogen.
| Adjusted absolute differences (95%CI) [CEE-E2] | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Progestogen use | Estrogen dose¶ | ||||||||
| Unopposed estrogens (without progestogen) § | Opposed estrogens (with progestogen) † | Low estrogen dose (CEE ≤0.3125mg or E2 ≤0.5mg/d) | Standard estrogen dose (CEE=0.625mg or E2=1mg/d) | ||||||
| E2 users (n=65) | CEE users (n=38) | E2 + MPA users (n=28) | CEE + MPA users (n=10) | E2 users (n=35) | CEE users (n=9) | E2 users (n=51) | CEE users (n=35) | ||
| Thrombin Generation | Peak value (nM) | Ref. | +42.8 ** (11.8 to 73.7) | Ref. | +92.4 * (4.1 to 180.8) | Ref. | +24.1 (−1.9 to 70.0) | Ref. | +65.3 ** (29.3 to 101.2) |
| ETP (nMxMin) | Ref. | +140.0 * (5.9 to 274.0) | Ref. | +400.4 * (65.5 to 735.4) | Ref. | −21.2 (−177.7 to 135.3) | Ref. | +227.0 *** (78.8 to 377.1) | |
| Lag-time (min) | Ref. | + 0.0 (−.3 to 0.4) | Ref. | − 0.10 (−0.6 to 0.4) | Ref. | −0.4 * (−0.7 to −0.1) | Ref. | +0.1 (−0.3 to 0.5) | |
| Time to peak (min) | Ref. | −0.1 (−0.5 to 0.3) | Ref. | −0.3 (−1.0 to 0.3) | Ref. | −0.8 * (−1.4 to −0.1) | Ref. | −0.2 (−0.7 to 0.3) | |
| Factor VII (%) | Ref. | −10.6 (−29.2 to 7.9) | Ref. | −2.1 (−20.4 to 16.2) | Ref. | −1.8 (−30.0 to 26.3) | Ref. | −6.4 (−26.7 to 13.9) | |
| Antithrombin (%) | Ref. | −0.4 (−6.6 to 5.8) | Ref. | −6.7 (−18.2 to 4.8) | Ref. | −7.8 (−20.6 to 5.0) | Ref. | +0.7 (−6.0 to 7.4) | |
| Total protein S (%) | Ref. | −13.7 *** (−21.6 to −5.7) | Ref. | −9.0 (−22.6 to 4.7) | Ref. | −15.1 * (−26.5 yo −3.6) | Ref. | −12.9 ** (−21.9 to −3.9) | |
§
Adjusted for age, race, BMI, cancer, FVL, use of statins, diabetes, dose of estrogen
†
Adjusted for age, race, BMI, cancer, FVL, use of statins, diabetes, dose of estrogen, dose of medroxyprogesterone acetate (progestogen)
¶
Excluding high-dose estrogen (n=15) and adjusted for age, race, BMI, cancer, FVL, use of statins, diabetes, use of medroxyprogesterone acetate.
All P-values for interaction by progestogen use or estrogen dose were >0.05 except the P-value by estrogen dose for the measurement of lag-time (p=0.014).
*
p<0.05 /
**
p<0.01 /
***
p<0.001;
ETP= endogenous thrombin potential